The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | What are the potential applications of MYC inhibition in oncology?
Laura Soucek, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses the future of OMO-103, a novel MYC inhibitor, and the potential indications it could be approved for. Whilst the drug can be used in all MYC-mutant tumors, pancreatic ductal adenocarcinoma (PADC) and non-small cell lung cancer (NSCLC) have been found to be particularly responsive to OMO-103. Combination therapies with chemotherapy or KRAS inhibitors in PADC and NSCLC respectively are additionally being assessed. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
